AbbVie drops lawsuit against EMA after data redaction agreed
This article was originally published in SRA
AbbVie has withdrawn its lawsuits against the European Medicines Agency after the agency accepted a new set of redacted documents submitted by AbbVie, along with the company's rationale for removing certain commercially confidential information from the clinical study reports that are at the center of the litigation1,2.
You may also be interested in...
The EU General Court has dismissed three cases by pharmaceutical companies that wanted to prevent the European Medicines Agency from disclosing certain data about their marketed medicines on the grounds that it would harm their commercial interests. Firms now have a clearer idea of the standards they will need to meet to claim their information is commercially confidential.
Two new quality guidelines are needed to address the increase in applications for clinical trials and marketing authorizations of oligonucleotide- and peptide-based medicines, says the EU regulator.
The European Commission has laid out a number of possibilities for changing the EU framework on compulsory licensing to improve the availability of products in health emergencies. The options include extending the scope of compulsory licences beyond patents to other forms of protection such as data exclusivity.